- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1073 |
Product Name |
ADT1073-Bavituximab Biosimilar-Anti-Phosphatidylserine mAb-Research Grade |
Alias |
Tarvacin ch3G4 |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse Phosphatidylserine antibody, anti-Phosphatidylserine antibody, anti Phosphatidylserine antibody, recombinant Phosphatidylserine, Phosphatidylserine antibody, anti-Phosphatidylserine monoclonal antibody, Phosphatidylserine antibodies, Phosphatidylserine recombinant antibody, Phosphatidylserine blocking antibody |
|
Host |
CHO Cells |
Species |
Human |
Target |
Phosphatidylserine |
Gene ID |
23761 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
648904-28-3 |
Chemical Formula |
C6446H9946N1702O2042S42 |
Product Description |
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. |
Mechanism of Action |
Bavituximab Anti-Cancer is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid that is exposed only on the surface of tumor blood vessel cells or on cells infected with certain viruses. Bavituximab binding to the tumor blood vessel cells alerts the body’s immune system to attack the tumor and its blood supply. This has been shown to Inhibitionit tumor growth and development. Because in healthy cells the phospholipids are concealed inside the cell, the bavituximab does not bind to them. This targets the bavituximab to the malignant cells and potentially minimizes unwanted side effects.
Bavituximab Anti-Viral represents a unique approach to treating viral diseases by recognizing features found only on infected cells and enveloped viruses. Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called an aminophospholipid that is exposed on the surface of cells only when they are infected with certain viruses or when they are malignant. After binding to these infected cells, the drug alerts the body’s immune system to attack the infected cells. This makes infected cells particularly susceptible to bavituximab treatment, while potentially sparing healthy cells. Also, bavituximab binds to phospholipids which are derived from the host (human) cell and not the virus, which indicates it may not be susceptible to viral drug resistance. In addition to treating an active illness, bavituximab may also confer long-term immunity. Bavituximab induces a pro-inflammatory cytokine profile, defined as an increase in the ratio of TNF alpha and TGF beta. Stimulating an immune response is a key proposed anti-viral mechanism of action of bavituximab.
|
Metabolism |
Bavituximab has a moderate to long half-life and is distributed throughout the bloodstream and tissues. |
Application |
Functional assay, IF, Neut, ELISA, FC, IP, ICC |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reactivity |
Human |
Reference |
1.Kumar S, et al. Biol Open, 2021 Mar 3. PMID 33593792
2.Zhao T, et al. Life Sci Alliance, 2019 Apr. PMID 30858161
3.Girisha KM, et al. Hum Mutat, 2019 Mar. PMID 30488656
|